Literature DB >> 7520517

Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade.

W H Harvey1, O S Harb, S T Kosak, J C Sheaffer, L R Lowe, N A Heerema.   

Abstract

ESKOL, a B-lymphoblastoid cell line consisting of late differentiated cells, resembles hairy cell leukemia (HCL). It is pseudodiploid with a deleted 7q and an unbalanced translocation between chromosomes 4 and 6. It was screened by Northern hybridization for oncogenes, including H-ras, c-raf-2 (c-raf1p1), c-kit, c-myc, c-myb, c-fos, Fim-1, c-jun, ski, and c-mos, which are believed to contribute to B-cell differentiation and maturation. Interferon-alpha-2b (IFN) downregulates the expression of H-ras, c-raf-2, c-kit, c-myc, c-myb, c-fos, as determined by Northern hybridization of RNA isolated from cells harvested at time points during a 30 h time course. Downregulation of oncogenes H-ras, c-raf-2, c-kit, whose proteins are associated with cell surfaces or are cytosolar transducers, occurs before those oncogenes c-myc, c-myb, and c-fos, whose products are DNA binding proteins. This suggests a temporal perturbation of signal transduction by IFN. No change in oncogene expression occurred in non-treated cells nor were these oncogenes expressed in the non-transformed B-lymphoblast cell line, Wil-2, under the same treatment regimen. The basis for the IFN perturbation is not understood; yet the role of these oncogenes as signal transducers in differentiation and proliferation of human hematopoietic progenitors is unfolding, and ESKOL is an excellent system in which to study this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520517     DOI: 10.1016/0145-2126(94)90039-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

2.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

3.  STAT1 modification improves therapeutic effects of interferons on lung cancer cells.

Authors:  Junjie Chen; Jialu Zhao; Lefu Chen; Nian Dong; Zhaojian Ying; Zhenzhen Cai; Dongxiang Ji; Yong Zhang; Li Dong; Yuping Li; Lei Jiang; Michael J Holtzman; Chengshui Chen
Journal:  J Transl Med       Date:  2015-09-08       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.